Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Rosetta Genomics begins miRview squamous comparison study with Johns Hopkins

Rosetta Genomics : 03 October, 2008  (Company News)
Rosetta Genomics has begun a clinical assessment study with the Johns Hopkins University School of Medicine to compare Rosetta Genomics' miRview squamous, which differentiates squamous from non squamous non small cell lung cancer, with available immunohistochemistry methods.
'We are excited to be collaborating once more with the excellent scientists at Johns Hopkins University,' said Dr Dalia Cohen. 'Having this microRNA-based test assessed for clinical validity by faculty at one of the country's top cancer research centres is viewed by us as a strong indication to the interest this product and our technology are generating in the oncology world.'

Differentiating squamous from non squamous cell lung cancer presents a challenge to physicians, but until recently this differentiation was not particularly relevant from a therapeutic or prognostic standpoint since no drug was designed for a specific NSCLC sub-type.

A recently approved angiogenesis inhibitor for NSCLC has been shown to have severe side effects for squamous-cell lung cancer patients. Furthermore, this targeted therapy includes a black-box warning about substantially higher rates of severe or fatal haemorrhage among NSCLC patients with predominantly squamous histology. This has led patients with squamous-cell histology to be regarded by many as inappropriate candidates for therapy with this drug. In addition, several other targeted drugs for NSCLC currently under development may require this type of accurate differentiation due to different side effect profiles or different levels of efficacy.

Combining Rosetta Genomics' proprietary microRNA extraction technology from FFPE samples, sensitive quantification platforms, and microRNA molecular biomarkers identified by the company, Rosetta Genomics has developed a test which differentiates squamous cell carcinoma of the lung from non-squamous NSCLC. The test, which is the subject of the study to be conducted at John Hopkins, is in the final stages of development and is expected to be commercially available by the fourth quarter of 2008.

In July 2008, Columbia University Medical Center's (CUMC) High Complexity Molecular Pathology Laboratory received the approval of the New York State regulators for a test differentiating Squamous NSCLC from other NSCLC. The test, which is based on Rosetta Genomics' technology, exhibited sensitivity of 96 percent and specificity of 90 percent.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo